[PDF] Top 20 Severe Ulcerative Colitis After Rituximab Therapy
Has 10000 "Severe Ulcerative Colitis After Rituximab Therapy" found on our website. Below are the top 20 most common "Severe Ulcerative Colitis After Rituximab Therapy".
Severe Ulcerative Colitis After Rituximab Therapy
... months after the onset of gas- trointestinal symptoms revealed com- plete resolution of the ulcers and inflammation in the entire gastrointes- tinal ...the severe gas- trointestinal disease, his NS remained ... See full document
6
Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients
... Infliximab has revolutionized the approach to the medical management of children and adolescents suffering from UC. In pediatric patients with UC treated with anti-TNF- α medica- tions, response and remission rates are ... See full document
8
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
... α therapy and had active disease (defined by a full Mayo score of 6–12 and an endoscopic subscore of 2–3), despite stable doses of concomitant steroids, immu- nomodulators, or ...with ulcerative ... See full document
8
Anti–TNF-α Therapy May Cause Neonatal Neutropenia
... To the best of our knowledge, there are no literature reports of neonatal neu- tropenia associated with the mother ’ s use of anti – TNF- a agents during pregnancy. Here, we report on 4 cases of severe ... See full document
7
<p>Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?</p>
... acute severe UC who were not steroid-refractory, indicating that in fl iximab may be an alternative to steroids in patients who cannot take ...with severe UC refractory to steroids, in which a “ single dose ... See full document
9
Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study
... months after the start of treatment between patients treated with anti-TNF- a agents and those treated with ...weeks after the start of remis- sion induction therapy was 55% in the TAC group and 57% ... See full document
10
Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial
... acute severe UC, who failed to respond to intraven- ous steroids, were recruited to the trial and randomly allocated to treatment with infliximab or ...acute severe ulcerative colitis used was ... See full document
14
Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study
... Material and methods. The analysis included 42 children aged 4–18 years (23 girls, 19 boys) treated in 7 pediatric gastroenterology departments in Poland during the past 4 years. The disease duration ranged from 2 to 100 ... See full document
5
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
... to severe active ulcerative colitis who have failed to respond or are poorly responsive to standard pharmacologic forms of treatment with corti- costeroids and immunosuppressive agents, ... See full document
6
Cost effectiveness of adalimumab, infliximab or vedolizumab as first line biological therapy in moderate to severe ulcerative colitis
... Related to the topic of considering individual patient needs, our model is limited to published data in ACT, ULTRA and GEMINI trials. Real-life dosing for biologics (especially in fl iximab) is often personalised, falling ... See full document
6
<p>Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy</p>
... of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental ...active ulcerative colitis in ...oral therapy is poised to be a mainstay of UC ... See full document
13
Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years
... Few C-reactive protein values were available, but, as expected, levels dropped in the period after IFX therapy. Only seven in both groups had C-reactive protein measured 1 month before and at variable time ... See full document
9
Abstract: Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about
... first-line therapy at Day 3 of IV corticosteroids ...corticosteroids therapy predicts first line treatment failure (sensitivity 85%, specificity 75%) and need for second-line therapy in 66% and ... See full document
14
Management of Acute Severe Colitis in Children With Ulcerative Colitis in the Biologics Era
... with ulcerative colitis will experience at least 1 attack of acute severe colitis (ASC) before 15 years of ...age. Severe disease can be defined in children when Pediatric ... See full document
11
<p>Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data</p>
... latest therapy to be approved for UC, its current use mostly assumes that of salvage ...improve therapy adherence and quality of life in patients averse to the requirement for long-term injections or ... See full document
15
Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease
... ied 30 patients with UC initially treated with sulfasalazine and glucocorticoids and then randomly administered either Bifid Triple Viable capsule or an identical placebo (starch). Fecal analysis and histological ... See full document
15
Evaluation of Protective Effect of Hydro-Alcoholic Extract of Fruits Peels of Punica Granatum Linn. Against Ulcerative Colitis In Rats
... The innate immune system is the body‘s nonspecific defense against pathogens; it responds immediately or within the first few hours after a challenge. This is commonly considered the first line of defense and ... See full document
104
Dying Tt Save Your Colon? Changing the Way We Look at Ulcerative Colitis
... With these insights, we conducted a discrete choice experiment to quantify the UC patients' mean maximum acceptable risk for life-threatening SAEs associated with immunosuppressant therapy to avoid colectomy ... See full document
130
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
... Abstract: Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory bowel disease, with a characteristic leukocytic infiltration of the ...anti-TNF-α therapy is a mainstay of ... See full document
10
Amino Acid Position 11 of HLA-DRβ1 is a Major Determinant of Chromosome 6p Association with Ulcerative Colitis
... Best model association results for ulcerative colitis versus Crohn’s disease with ileal involvement Table 5A, ulcerative colitis versus control using markers from 5A Table 5B and Crohn’s[r] ... See full document
20
Related subjects